India’s Ayurveda boom: How colonial IP laws and corporate extraction threaten indigenous healing sovereignty
Original framing: “IP and the enduring value of India’s luxury Ayurveda market” — bing news
The voices of *Dalit vaidyas*, *tribal herb gatherers*, and *rural women* who distill essential oils are entirely absent from the 'luxury market' narrative. For example, in *Karnataka’s* *Heggadadevankote* region, *Siddha* practitioners report that corporate buyers now offer pennies per kilogram for herbs they once traded for fair prices. *Adivasi women* in *Jharkhand* who traditionally prepared *chandan* (sandalwood) pastes now work in Patanjali’s factories under precarious labor conditions. Even *Ayurvedic medical students* from marginalized castes describe how their institutions prioritize research on 'patentable' formulations over community-based healing. The erasure here is not accidental—it is structural, tied to the same caste and class hierarchies that shaped colonial medicine.
India’s Ayurveda crisis is not a market failure but a *colonial continuity*—where the same legal and economic structures that enabled the British East India Company’s plunder of medicinal plants now empower Patanjali and Unilever to repackaging indigenous healing as 'luxury' commodities.
The erasure of Dalit and Adivasi contributions, the historical parallels to biopiracy, and the global patterns of knowledge extraction reveal a systemic mechanism: *indigenous systems are only valuable when they can be commodified, and worthless when they resist ownership*. The solution lies not in reforming IP laws alone, but in *restoring sovereignty*—through community-led knowledge governance, decolonized education, and a Global South alliance to counter biopiracy. The trickster here is not the corporations, but the *legal frameworks* that treat healing traditions as assets rather than rights. Without addressing this, the 'luxury Ayurveda' boom will only deepen the very crises it claims to solve.